Close Menu

marketing agreement

The agreement follows yesterday's announcement of a similar pact with Ion Torrent.

As part of the deal, FIND will have rights to sell the HIV test, as well as Cepheid's Xpert chlamydia and gonorrhea tests, which will be sold at a discount to the public and the not-for-profit sector in some countries.

Ion Torrent will offer software from Partek and DNAStar directly through its online store, and it has inked a service and support deal with BioTeam for the Ion Torrent Server and Torrent Suite Software.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

The instruments were acquired just three months ago by Cellectis from Cyto Pulse Sciences.

LightArray will offer a variety of Aushon's multiplex biomarker products and services in China.

Rosetta has regained US commercial rights from Prometheus for its miRview mets, miRview squamous, and miRview meso tests.

Cepheid will receive $5 million in an upfront payment and $3 million in milestone payments over the next 12 months as part of the deal, while Novartis would have exclusive global distribution rights to the test upon its commercialization in the US.

Abbott will be the exclusive distributor of the KIF6 test in the European Union and other areas that recognize the CE mark.

Waters expects the deal to result in its products being offered to a broader use base.


NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.